산업동향
Introducing the Pharma 2020 series
- 등록일2012-09-17
- 조회수4731
- 분류산업동향 > 제품 > 바이오의약
-
자료발간일
2011-07-07
-
출처
http:// www.pwc.com
-
원문링크
-
키워드
#Pharma 2020 series
- 첨부파일
Introducing the Pharma 2020 series
The Pharmaceutical industry's long successful strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters worked well for many years, but its R&D productivity has now plummeted and the environment’s changing. PwC1 believes that seven major trends are reshaping the marketplace:
□ Instances of chronic disease are increasing, placing even greater pressure on already
stretched healthcare budgets
□ Healthcare policy-makers and payers are increasingly mandating what doctors can
prescribe
□ A growing number of healthcare payers are measuring the pharmacoeconomic
performance of different medicines. A widespread use of electronic medical records will
give them the data they need to insist on outcomes-based pricing
□ Boundaries between different forms of healthcare are blurring, as clinical advances render
previously fatal diseases chronic and the self-medication sector expands
□ Demand for medicines is growing more rapidly in the emerging economies than the
industrialized economies
□ Governments are beginning to focus on prevention rather than treatment, although they
have not yet invested very much in pre-emptive measures; and
□ Regulators are becoming more cautious about approving truly innovative medicines.
These trends will compound the challenges Pharma already faces, but they’ll also provide some major opportunities.
So what must the industry do to capitalise on them?
We think that it’ll have to improve its understanding of disease, reduce its R&D costs significantly and spread its bets to improve its productivity. It’ll also have to tap the potential of the emerging economies and switch from selling medicines to managing outcomes. However, few, if any, companies will be able to perform these activities alone.
.....(계속)
☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다.